This category page covers biotechnology and pharmaceutical companies developing NRF2 activators, KEAP1 inhibitors, and antioxidant response modulators specifically for Parkinson's disease. The Nrf2-KEAP1 pathway is the primary cellular defense mechanism against oxidative stress, which is a central pathological feature of PD. Activation of Nrf2 leads to upregulation of antioxidant genes, enhancement of mitochondrial function, suppression of neuroinflammation, and protection of dopaminergic neurons.
This page complements the broader AD Nrf2-Keap1 Pathway Companies page with a specific focus on Parkinson's disease programs.
The Nrf2 pathway is particularly relevant for Parkinson's disease because:
| Approach | Description | Companies |
|---|---|---|
| Direct Nrf2 Activators | Covalent or non-covalent KEAP1 binders that release Nrf2 | Evgen Pharma, Biogen |
| Keap1 Inhibitors | Disrupt Keap1-Nrf2 binding interface | Nacuity, Evotec |
| Sulforaphane Derivatives | Natural product-based Nrf2 activators with optimized formulations | Evgen Pharma |
| ARE Modulators | Direct modulation of antioxidant response element transcription | Various research-stage |
| Gene Therapy | AAV-mediated NFE2L2 delivery to substantia nigra | Research-stage |
Evgen Pharma is the most advanced company with a dedicated Parkinson's disease program for Nrf2 activation.
Biogen has explored repurposing dimethyl fumarate (Tecfidera), already approved for multiple sclerosis, for Parkinson's disease.
Reata Pharmaceuticals (acquired by Alnylam in 2023) developed bardoxolone methyl, one of the most potent direct Nrf2 activators.
Nacuity Pharmaceuticals is an Australian biotech with a selective Nrf2 activator in preclinical development for Alzheimer's disease, with potential extension to PD:
Nacuity Pharmaceuticals company page
Multiple academic groups have Nrf2-NPD programs in various stages:
| Organization | Program | Stage | Notes |
|---|---|---|---|
| Keapstone Therapeutics (U. Edinburgh) | Keap1-Nrf2 modulators | Preclinical | Spinout from Nrf2 biology research |
| Evotec | High-throughput Keap1 screening | Discovery | Partnered with pharma on CNS Nrf2 programs |
| University of Pittsburgh | AAV-NFE2L2 gene therapy | Preclinical | Direct substantia nigra injection in models |
| Scripps/UC Irvine | Novel Nrf2 activators | Preclinical | Non-electrophilic scaffold identification |
| Company | Drug/Program | Mechanism | PD Stage | Notes |
|---|---|---|---|---|
| Evgen Pharma | SFX-01 | Sulforaphane Nrf2 activator | Phase 1/2 | Oral, stabilized formulation |
| Biogen | Dimethyl fumarate | Nrf2 activator + HCA2 | Phase 2 (completed) | Repurposed MS drug |
| Alnylam (Reata) | Bardoxolone methyl | Direct Nrf2 activator | Phase 1/2 (completed) | Acquired 2023 |
| Nacuity Pharma | NPI-001 | Selective Nrf2 activator | Preclinical AD | Potential PD extension |
| Evotec | Keap1 inhibitors | Keap1-Nrf2 disruptors | Discovery | Pharma partnerships |
| University groups | AAV-NFE2L2 | Gene therapy | Preclinical | Research-stage |
| Trial ID | Drug | Phase | Status | Key Endpoints |
|---|---|---|---|---|
| NCT03425656 | Dimethyl fumarate | Phase 2 | Completed | MDS-UPDRS, safety |
| NCT04477210 | Sulforaphane | Phase 1 | Completed | Safety, CSF biomarkers |
| — | SFX-01 (Evgen) | Phase 1/2 | Planned | Motor scores, oxidative stress biomarkers |
| — | Bardoxolone methyl | Phase 1/2 | Completed | Safety, mitochondrial function |
Key biomarkers used to demonstrate target engagement:
The Nrf2-KEAP1 pathway operates through the following cascade in PD:
| Nrf2 Target | Neuroprotective Effect in PD |
|---|---|
| HO-1 | Degrades pro-oxidant heme; generates biliverdin/bilirubin antioxidants |
| NQO1 | Prevents redox cycling of quinones from dopamine oxidation |
| GCLC/GCLM | Increases glutathione synthesis — primary neuronal antioxidant |
| PGC-1alpha | Mitochondrial biogenesis; counters Complex I deficiency |
| p62 | Autophagy activation; clears alpha-synuclein aggregates |
| Hsp70 | Chaperone protection against proteotoxic stress |
Last et al. Nrf2 activators in Parkinson's disease clinical trials. Movement Disorders. 2022. ↩︎
Bahn et al. Dimethyl fumarate in Parkinson's disease. Parkinsonism and Related Disorders. 2019. ↩︎